Stemline Therapeutics (STML) Tops Q3 EPS by 5c

Stemline Therapeutics (NASDAQ: STML) reported Q3 EPS of ($0.53), $0.05 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $71.4 thousand versus the consensus estimate of $80 thousand.

For earnings history and earnings-related data on Stemline Therapeutics (STML) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Inhibrx, Inc. (INBX) Misses Q2 EPS by 54c
• Hitachi Ltd. (HIT) Misses Q2 EPS by 7c